Online inquiry

IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8570MR)

This product GTTS-WQ8570MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD47 gene. The antibody can be applied in Colorectal Cancer (CRC) Cancers (CRC) Cancers(CRC), Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001777.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 961
UniProt ID Q08722
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8570MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7347MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA FPA-150
GTTS-WQ14910MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ9671MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ3812MR IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BB-10901
GTTS-WQ2580MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 531
GTTS-WQ9432MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IPH-2201
GTTS-WQ9660MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ79MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA (131)I-chTNT-1/B
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW